Why is Marksans Pharma falling/rising?

As of 25-Jul, Marksans Pharma Ltd is experiencing a decline in its stock price, currently at Rs 228.00, reflecting a decrease of Rs 3.8 or 1.64%. The stock has been underperforming significantly, having fallen for the last eight consecutive days, resulting in a total decline of 12.98% during this period. Additionally, it is trading below all key moving averages, indicating a bearish trend. Despite a high return on equity of 17.66% and low debt-to-equity ratio, the company has shown poor long-term growth with an operating profit growth rate of only 2.87% over the last five years. This, combined with flat results in March 2025 and a relatively high price-to-book value, suggests that the stock may be overvalued, contributing to its recent price decline.
In the broader market context, Marksans Pharma's short-term performance has been notably worse than the benchmark, with a one-week return of -11.18% compared to the Sensex's -0.36%. Over the past month, the stock has also underperformed the benchmark, showing a decline of 7.69% against the Sensex's 1.56% drop. While the stock has generated a positive return of 13.80% over the past year, this is overshadowed by its year-to-date decline of 23.04%, contrasting sharply with the Sensex's gain of 4.25%. The rising investor participation, indicated by a significant increase in delivery volume, may suggest some interest, but the overall negative sentiment and recent performance indicate a challenging environment for Marksans Pharma.